Precision medicine in acute myeloid leukemia

Hope, hype or both?

Vinay Prasad, Robert Peter Gale

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Precision medicine is interchangeably used with personalized medicine, genomic medicine and individualized medicine. Collectively, these terms refer to at least 5 distinct concepts in the context of AML. 1st, using molecular or omics data (e.g. genomics, epigenomics, transcriptomics, proteomics) to delineate or define subtypes of AML. 2nd, using these data to select the best therapy for someone with an AML subtype, such as a person with a FLT3-mutation. 3rd, using these data to monitor therapy-response such as measurable residual disease [MRD]-testing. 4th, using results of MRD-testing to select from amongst therapy-options such as additional chemotherapy or a haematopoietic cell transplant. And 5th, using these data to identify persons with hereditary forms of AML with potential therapy and surveillance implications. Here, we review these 5 conceptions and delineate where precision medicine is likely to afford greatest hope and where instead our rhetoric may constitute hype.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalLeukemia Research
Volume48
DOIs
StatePublished - Sep 1 2016

Fingerprint

Precision Medicine
Acute Myeloid Leukemia
Therapeutics
Genomics
Epigenomics
Proteomics
Medicine
Transplants
Drug Therapy
Mutation

Keywords

  • AML
  • Individualized medicine
  • Molecular medicine
  • Precision medicine

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Precision medicine in acute myeloid leukemia : Hope, hype or both? / Prasad, Vinay; Gale, Robert Peter.

In: Leukemia Research, Vol. 48, 01.09.2016, p. 73-77.

Research output: Contribution to journalArticle

@article{66b994c86ceb40258dbc07d5d8024d00,
title = "Precision medicine in acute myeloid leukemia: Hope, hype or both?",
abstract = "Precision medicine is interchangeably used with personalized medicine, genomic medicine and individualized medicine. Collectively, these terms refer to at least 5 distinct concepts in the context of AML. 1st, using molecular or omics data (e.g. genomics, epigenomics, transcriptomics, proteomics) to delineate or define subtypes of AML. 2nd, using these data to select the best therapy for someone with an AML subtype, such as a person with a FLT3-mutation. 3rd, using these data to monitor therapy-response such as measurable residual disease [MRD]-testing. 4th, using results of MRD-testing to select from amongst therapy-options such as additional chemotherapy or a haematopoietic cell transplant. And 5th, using these data to identify persons with hereditary forms of AML with potential therapy and surveillance implications. Here, we review these 5 conceptions and delineate where precision medicine is likely to afford greatest hope and where instead our rhetoric may constitute hype.",
keywords = "AML, Individualized medicine, Molecular medicine, Precision medicine",
author = "Vinay Prasad and Gale, {Robert Peter}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2016.07.011",
language = "English (US)",
volume = "48",
pages = "73--77",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Precision medicine in acute myeloid leukemia

T2 - Hope, hype or both?

AU - Prasad, Vinay

AU - Gale, Robert Peter

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Precision medicine is interchangeably used with personalized medicine, genomic medicine and individualized medicine. Collectively, these terms refer to at least 5 distinct concepts in the context of AML. 1st, using molecular or omics data (e.g. genomics, epigenomics, transcriptomics, proteomics) to delineate or define subtypes of AML. 2nd, using these data to select the best therapy for someone with an AML subtype, such as a person with a FLT3-mutation. 3rd, using these data to monitor therapy-response such as measurable residual disease [MRD]-testing. 4th, using results of MRD-testing to select from amongst therapy-options such as additional chemotherapy or a haematopoietic cell transplant. And 5th, using these data to identify persons with hereditary forms of AML with potential therapy and surveillance implications. Here, we review these 5 conceptions and delineate where precision medicine is likely to afford greatest hope and where instead our rhetoric may constitute hype.

AB - Precision medicine is interchangeably used with personalized medicine, genomic medicine and individualized medicine. Collectively, these terms refer to at least 5 distinct concepts in the context of AML. 1st, using molecular or omics data (e.g. genomics, epigenomics, transcriptomics, proteomics) to delineate or define subtypes of AML. 2nd, using these data to select the best therapy for someone with an AML subtype, such as a person with a FLT3-mutation. 3rd, using these data to monitor therapy-response such as measurable residual disease [MRD]-testing. 4th, using results of MRD-testing to select from amongst therapy-options such as additional chemotherapy or a haematopoietic cell transplant. And 5th, using these data to identify persons with hereditary forms of AML with potential therapy and surveillance implications. Here, we review these 5 conceptions and delineate where precision medicine is likely to afford greatest hope and where instead our rhetoric may constitute hype.

KW - AML

KW - Individualized medicine

KW - Molecular medicine

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=84982698628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982698628&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.07.011

DO - 10.1016/j.leukres.2016.07.011

M3 - Article

VL - 48

SP - 73

EP - 77

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -